Table of Contents Table of Contents
Previous Page  36 / 60 Next Page
Show Menu
Previous Page 36 / 60 Next Page
Page Background


NCCN Guidelines for Patients



Waldenström’s Macroglobulinemia, Version 1.2017

Part 4 describes treatment options for

people with WM. Patients with WM

who have symptoms receive treatment.

Options for primary treatment are listed in

Guide 4. Guide 5 describes the response

to primary treatment. Guide 6 lists next

steps based on the response. Guide 7

lists further treatment for WM.

This information is taken from the treatment

guidelines written by NCCN experts of WM. These

treatment guidelines list options for people with WM

in general. Thus, your doctors may suggest other

treatment for you based on your health and personal

needs. Discuss and decide on your treatment plan

with your doctor.

Primary treatment

Your doctor may begin with plasmapheresis. You can

get this treatment before systemic therapy is given.

Plasmapheresis is done to reduce IgM in the blood

that causes hyperviscosity and its symptoms. This

type of treatment can prepare your body for the next

treatment in line. These options include drugs that

are non-stem cell toxic treatment. These drugs will

not limit your options for future treatment such as a

stem cell transplant.

A stem cell transplant may be an option for a small

number of people with WM, especially people with

complications of amyloid or who have had multiple

relapses. For example, a younger person may have

a stem cell transplant in the future. If this is the case,

he or she will likely not get certain drugs that can

cause damage to normal blood cells, especially if

given often. Such damage to cells could possibly

lead to other types of serious blood problems, un-

related to WM, such as myelodysplasia and even



Treatment guide

Primary treatment